A carregar...
Publicação
An estimate of the economic impact of immunotherapy relative to PD-L1 expression in Brazil - An update with brazilian costs
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 92.06 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Delivering high quality cancer care at an affordable cost is one of the main challenges for health care professionals and policy makers, especially in lowand middle-income countries. The objective of our study is to assess the economic impact of nivolumab and
pembrolizumab with and without the use of PD-L1 as a biomarker in Brazil.